GlassScriptPrepare for your visit
Sharon Mccormack
Internal Medicine · Baltimore, MD · NPI 1013902899
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$490.86
in general payments reported to CMS, 2019-2025 · $135 in 2025
The $135 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Who reported paying
General payments only, top 6 by amount.
- E.R. Squibb & Sons, L.L.C. $118.42
- Advanced Accelerator Applications $112.81
- Novo Nordisk INC $105.58
- Pharmacyclics LLC, An Abbvie Company $41.18
- Abbott Laboratories $29.48
- Sunovion Pharmaceuticals INC. $23.09
Drugs and devices associated with these payments
Ozempic Eterna Vyndamax
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Sharon Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/182524/sharon-mccormack